Las Vegas Doctor Loses DEA License Over Suspended State Permit
Published Date: 4/16/2025
Notice
Summary
Dr. Ajumobi Agu from Las Vegas lost his DEA license because he kept giving out controlled medicines after his state licenses were suspended. Since he didn’t ask for a hearing, the DEA decided to revoke his registration to keep the public safe. This means he can’t legally handle controlled substances anymore, effective immediately, protecting patients and the community.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Agu
The DEA revoked Ajumobi Agu, M.D.'s Certificate of Registration No. FA4195459 and denied any pending applications to renew, modify, or add a registration in Nevada. The revocation takes effect May 16, 2025, so Dr. Agu may no longer legally handle controlled substances under that DEA registration.
Public Safety Protected by Revocation
The DEA revoked Dr. Agu's registration to protect patients and the public after finding he issued about 22 controlled-substance prescriptions to 14 patients between June 30, 2023 and September 11, 2023 while his Nevada licenses were suspended. The Order is effective May 16, 2025, and aims to prevent further dispensing of controlled medicines by this registrant in Nevada.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
2026-12654 — Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
Previous / Next Documents
Previous: 2025-06451 — Lattice-Boom Crawler Cranes (LBCCs) From Japan; Institution of Antidumping Duty Investigation and Scheduling of Preliminary Phase Investigation
The U.S. is launching an investigation to see if cheap lattice-boom crawler cranes from Japan are hurting American businesses. If they find unfair pricing, extra taxes might be added to these imports. The investigation’s first big decision is due by May 27, 2025, so things are moving fast!
Next: 2025-06453 — Victor Augusto Silva, M.D.; Order
Dr. Victor Augusto Silva from Tampa had his DEA registration suspended and then revoked because he let someone else illegally use his license to prescribe drugs. Since he didn’t respond in time to defend himself, the government decided he’s a risk to public safety and took away his registration for good. This means he can’t legally prescribe controlled substances anymore, effective immediately.